In order to provide emergency medical care to a limited population of patients with especially severe pathology, on November 25, 2020, Chairman of the Government of the Russian Federation M.V. Mishustin by Order No. 3100-r authorized the Federal State Unitary Enterprise "Moscow Endocrine Plant" (hereinafter referred to as the Enterprise) to purchase and import, in accordance with the established procedure, a medicinal product not registered in the Russian Federation in the national packaging of a foreign manufacturer with the international non-proprietary name "Melphalan" (lyophilisate for the preparation of a solution for intravascular administration complete with a solvent) in the amount of 2500 packs with subsequent transfer to medical institutions determined by the Ministry of Health of Russia.
The drug "Melphalan" belongs to the pharmacotherapeutic group of antineoplastic agents, alkylating compounds and is used to treat cancer patients with especially severe pathology (multiple myeloma, progressive ovarian cancer, polycythemia vera).
On November 27, 2020, a supply agreement was signed between the Enterprise and the Irish company Aspen Pharma Trading Limited, on the basis of which the drug Melphalan would be supplied to the Russian Federation in the specified volume by the end of 2020.
Comment type is not specified in the component properties.